Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio ...

Small-group instruction has been a popular component of K-3 literacy education for many years. However, there are inevitable ...

The CUTX-101 NDA was initially granted Priority Review by the FDA and is supported by positive topline clinical efficacy results for CUTX-101, demonstrating significant improvement in overall survival ...

Sentynl Therapeutics, Inc. ("Sentynl"), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. ("Zydus Group"), today announced that the U.S. Food and Drug Administration (FDA ...

Dyne Therapeutics, Inc.’s 2026 outlook with key DYNE-101/251 data, FDA submission plans, and extended cash runway. Click for ...

Arovella Therapeutics Limited ( ($AU:ALA) ) has shared an announcement. Arovella Therapeutics Limited has issued 371,187 ordinary shares without ...

Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses([1]) , while ...

In a major leap for genomic medicine and the government’s commitment to tribal health, India on Wednesday launched its first indigenous CRISPR-based gene therapy aimed at eradicating Sickle Cell ...

New Delhi, Nov 19: In a major leap for Atmanirbhar Bharat and India’s genomic medicine capabilities, the government on Wednesday launched the country’s first indigenous CRISPR-based gene therapy for ...

CoTx-101 targets retinal vascular diseases using a novel vector, coAAV-SCS, for enhanced retinal penetration and sustained biologic expression. Coave Therapeutics plans to complete non-human primate ...

Kyverna Therapeutics has reported deep, sustained improvements in autoimmune disease patients who received a single dose of its CAR T-cell therapy KYV-101. The data come from the phase 2 part of a ...

Microbiotix Co. Ltd. has obtained IND approval from the Korean Ministry of Food and Drug Safety (MFDS) for MP-101, a bacteriophage therapy for patients with acute pneumonia. A phase I study in adult ...